Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Thursday

Key Points

• Corvus Pharmaceuticals is set to announce its Q2 2025 earnings on August 5th, with analysts expecting a loss of ($0.13) per share.
• Following a recent sale of shares by a director, the company's stock has experienced a 1.3% decline, opening at $4.65.
• Corvus Pharmaceuticals has a consensus rating of "Moderate Buy" based on recent analyst reviews, with target prices ranging up to $17.00.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.13) per share for the quarter.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Corvus Pharmaceuticals Price Performance

Shares of NASDAQ:CRVS traded down $0.07 during mid-day trading on Friday, hitting $4.10. The company had a trading volume of 604,705 shares, compared to its average volume of 832,279. The firm has a fifty day moving average price of $4.11 and a 200 day moving average price of $4.09. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $10.00. The company has a market capitalization of $279.50 million, a PE ratio of -4.18 and a beta of 0.58.

Wall Street Analyst Weigh In

CRVS has been the topic of several research reports. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, May 20th. Oppenheimer reissued an "outperform" rating and set a $17.00 price objective (up from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Finally, Wall Street Zen lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, May 20th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Corvus Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $15.00.

Insiders Place Their Bets

In other Corvus Pharmaceuticals news, Director Peter A. Thompson sold 1,176,332 shares of the company's stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the transaction, the director directly owned 7,165,006 shares in the company, valued at $29,806,424.96. This represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 28.50% of the stock is owned by insiders.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.